Abstract:Seiko Miyata, 1, &ast Kunihiro Iwamoto, 1, &ast Ippei Okada, 1, &ast Akihiro Fujimoto, 2 Yuki Kogo, 2 Daisuke Mori, 1, 3, 4 Manabu Amano, 5 Nao Matsuyama, 5 Kazuki Nishida, 5 Masahiko Ando, 5 Toshiaki Taoka, 6 Shinji Naganawa, 7 Norio Ozaki 1, 4 1 Department of Psychiatry, Nagoya University, Graduate School of Medicine, Nagoya, Japan; 2 Medical Headquarters, Eisai Co., Ltd., Tokyo, Japan; 3 Brain and Mind Research Center, Nagoya University, Nagoya, Japan; 4 Pathophysiology of Mental Disorders, Nagoya University, Graduate School of Medicine, Nagoya, Japan; 5 Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan; 6 Department of Innovative Biomedical Visualization (Ibmv), Nagoya University, Graduate School of Medicine, Nagoya, Japan; 7 Department of Radiology, Nagoya University, Graduate School of Medicine, Nagoya, Japan &astThese authors contributed equally to this work Correspondence: Seiko Miyata, Department of Psychiatry, Nagoya University, Graduate School of Medicine, 65 Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan, Tel +81 52 744 2282, Fax +81 52 744 2293, Email Purpose: Both subjective and objective evaluations are essential for the treatment of insomnia. Lemborexant has been shown to be effective in the long-term based solely on a subjective basis, and no long-term objective measures have been evaluated under natural sleep conditions. Small, lightweight sleep electroencephalogram (EEG) monitor was used, instead of polysomnography, to objectively evaluate sleep at home 4 and 12 weeks after lemborexant treatment. Patients and Methods: Adults and elderly subjects with insomnia disorder, per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, were enrolled in this open-label, single-arm, single-center trial. Objective and subjective measures of sleep were prospectively assessed. Sleep disturbance, excessive sleepiness, and depressive symptoms were assessed using questionnaires. Results: A total of 45 subjects were screened, of which 33 were enrolled. Paired t-tests were conducted to evaluate changes in sleep variables and compared with the baseline; subjects showed significant improvements in objective sleep efficiency (SE) and subjective sleep parameters at weeks 4 and 12 following treatment with lemborexant. When baseline values were taken into account, a repeated-multivariate analysis of variance (MANOVA) revealed statistically significant changes in the objective measures. Sleep disturbance, excessive sleepiness, and depressive symptoms improved after three months of lemborexant treatment. Conclusion: Furthermore, lemborexant therapy improved nocturnal sleep, when measured objectively using sleep EEG monitoring at home, and improved daytime sleepiness and depressive symptoms in older adults with insomnia disorder. Keywords: insomnia, lemborexant, objective sleep evaluation, portable sleep EEG monitoring, subjective sleep evaluation Insomnia is one of the most common sleep disorders encountered in geriatric clinics. The overall prevalences of insomnia symptoms ranges from 20% to 46% in the elderly, 1,2 and estimated overall prevalence of insomnia among Japanese was 17.3%. 3 Complaints of insomnia among the elderly were 1.3 times higher than among the young. 4 Epidemiologic studies have linked insomnia symptoms to the development of other diseases, including type 2 diabetes, dementia, stroke, and chronic kidney disease. 5–8 Furthermore, insomnia increases the risk of developing depression, 9 industrial and traffic accidents, 10,11 impaired working memory, 12 and decreased cortical oxygenation during a word fluency task. 13 In recent years, cognitive behavioral therapy has been recommended as the first-line treatment for chronic insomnia in adults of any age. 14,15 However, pharmacological therapy, including over-the-counter sleep aids, is the most widely used treatment for insomnia. 14,15 Older adults may be more vulnerable than younger adults to the adverse events associated with commonly prescribed sedative-hypnotics, 16 such as residual morning somnolence, daytime cognitive and psychomotor impairment, falls, and fractures. 17,18 In a recently published meta-analysis, the orexin receptor antagonist, lemborexant, showed good efficacy, tolerability, and safety among all hypnotics for adults diagnosed with insomnia disorder. 19 Previous research has compared the eff -Abstract Truncated-

Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder

Efficacy and safety of insomnia treatment with lemborexant in older adults: analyses from three clinical trials

Exposure-Response Analyses of Polysomnography and Subjective Sleep Efficacy End Points From the Phase 3 Trials of Lemborexant, a Dual Orexin Receptor Antagonist for the Treatment of Insomnia

Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder

Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant

Respiratory Safety of Lemborexant in Healthy Subjects: A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Crossover Study

Assessing the Real-World, Long-Term Impact of Lemborexant on Sleep Quality in a Home-Based Clinical Study

Respiratory safety of lemborexant in adult and elderly subjects with moderate‐to‐severe chronic obstructive pulmonary disease

The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis

Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis

Short-Term Efficacy and Safety of Suvorexant and Lemborexant: A Retrospective Study

Efficacy of Lemborexant in Adults ≥ 65 Years of Age with Insomnia Disorder

Efficacy and Safety of Lemborexant for Insomnia Patients With Nocturia—A Prospective Study

Determination of thresholds for minimally important difference and clinically important response on the functional outcomes of sleep questionnaire short version in adults with narcolepsy or obstructive sleep apnea

0592 Efficacy of Lower-Sodium Oxybate by Baseline Sleep Inertia in a Phase 3 Clinical Study in Patients With Idiopathic Hypersomnia

0640 Magnitude of Improvement in Excessive Daytime Sleepiness with the Once-at-Bedtime Oxybate for Narcolepsy

Efficacy And Safety of Dual Orexin Receptor Antagonist (DORA) For Sleep Disturbance in Patients With Alzheimer's Disease Dementia. A Review Article

Improvement in sleep latency with extended-release once-nightly sodium oxybate for the treatment of adults with narcolepsy: Analysis from the phase 3 REST-ON clinical trial

0390 Efficacy of Suvorexant for Insomnia Disorder in Well-controlled Restless Legs Syndrome

Weight Loss With Once-nightly Sodium Oxybate for the Treatment of Narcolepsy: Analysis From the Phase III Randomized study Evaluating the efficacy and SafeTy of a ONce nightly formulation of sodium oxybate (REST-ON) Trial

0224 Chronic change in sleep oscillation expression in older adults with insomnia with zolpidem or lemborexant and its effect on memory